12,938 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by Royce & Associates LP

Royce & Associates LP purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,938 shares of the specialty pharmaceutical company’s stock, valued at approximately $468,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $72,000. Venturi Wealth Management LLC bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $92,000. KBC Group NV increased its stake in Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 929 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $211,000.

Supernus Pharmaceuticals Stock Down 0.5 %

Shares of SUPN stock opened at $32.15 on Friday. The company has a 50 day moving average price of $35.68 and a 200-day moving average price of $35.07. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The firm has a market capitalization of $1.79 billion, a PE ratio of 30.05 and a beta of 0.83.

Analyst Ratings Changes

A number of research firms have weighed in on SUPN. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 16th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last three months. 9.30% of the stock is currently owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.